TherapyTherapyТерапия2412-40362713-1823Bionika Media277669ArticlesСтатьиReview ArticleNolodotak (flupirtine) in treatment of patients with dorsopathyНолодотак (флупиртин) в лечении пациентов с дор-сопатиейKamchatnovPavel R.КамчатновПавел Рудольфович

MD, professor of the Department of neurology, neurosurgery and medical genetics

д.м.н., профессор кафедры неврологии, нейрохирургии и медицинской генетики

pavkam7@gmail.comKhanmurzaevaNaida B.ХанмурзаеваНаида Багавдиновна

PhD, assistant of the

к.м.н., ассистент кафедры фармакологии

KhanmurzaevaSaida B.ХанмурзаеваСаида Багавдиновна

assistant of the Department of nervous diseases, medical genetics and neurosurgery

ассистент кафедры нервных болезней, медицинской генетики и нейрохирургии

N.I. Pirogov Russian national medical research universityГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова»Dagestan state medical universityФГБОУ ВО «Дагестанский государственный медицинский университет»150320173NO3 (2017)№3 (2017)768322022023Copyright ©; 2017, Bionika MediaCopyright ©; 2017, ООО «Бионика Медиа»2017Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2412-4036/article/view/277669

Dorsopathy (DP) is the most common variant of musculoskeletal pain syndromes. Taking into account the chronic course of the disease with a tendency to recurrence, the high incidence of comorbid conditions, the need for a large number of medications, a serious problem is the choice of an effective drug with sufficient safety for use in individual patient. The article presents data on the possibility of the use of flupirtine, an original drug with the ability to activate potassium channels, providing analgesic and anti-spasmodic effects. The safety of the drug in patients with DP is analyzed.

Дорсопатия (ДП) - наиболее распространенный вариант скелетно-мышечного болевого синдрома. Учитывая хроническое, со склонностью к рецидивированию течение заболевания, высокую частоту коморбидных состояний, потребность в приеме большого количества лекарственных препаратов, серьезной проблемой является выбор эффективного препарата, обладающего достаточной безопасностью применения у конкретного больного. Приводятся сведения о возможности применения при ДП флупиртина - препарата, обладающего способностью активировать калиевые каналы, оказывая противоболевой и противоспастический эффекты. Анализируются вопросы безопасности применения препарата у пациентов с ДП.

lumbar painmusculoskeletal pain syndromesflupirtineNolodotaktreatmenthepatotoxicityдорсопатияскелетно-мышечные болевые синдромыфлупиртинНолодатакгепатотоксичностьCDC. National Ambulatory Medical Care Survey: 2010 Summary Tables. Table 9. www.cdc.gov/nchs/data/ahcd/ namcs_summary/2010_namcs_ web_tables.pdf. Accessed March 29, 2016.Vos T., Flaxman A., Naghavi M., et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163-96.Davies C., Nitz A., Mattacola C., Kitzman P., Howell D., Viele K., Baxter D., Brockopp D. Practice patterns when treating patients with low back pain: a survey of physical therapists. Physiother. Theory Pract. 2014;30(6):399-408.American College of Radiology. ACR Appropriateness Criteria. Low back pain. 2015. www.acr.org/~/media/ACR/ Documents/AppCriteria/Diagnostic/LowBackPain.pdf. Accessed March 10, 2016.Wong J., Cote P., Sutton D., Randhawa K., Yu H., Varatharajan S., Goldgrub R., Nordin M., Gross D.P., Shearer H.M., Carroll L.J., Stern P.J., Ameis A., Southerst D., Mior S., Stupar M., Varatharajan T., Taylor-Vaisey A. Clinical practice guidelines for the noninvasive management of low back pain: A systematic review by the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration. Eur. J. Pain. 2017;21(2):201-6.Cutforth G., Peter A., Taenzer P. The Alberta health technology assessment (HTA) ambassador program: The development of a contextually relevant, multidisciplinary clinical practice guideline for non-specific low back pain: A review. Physiother. Can. 2011;63:278-86.Livingston C., King V., Little A. et al. Evidence-based clinical guidelines project. Evaluation and management of low back pain: a clinical practice guideline based on the joint practice guideline of the american college of physicians and the American Pain Society. Salem, Oregon: Office for Oregon Health Policy and Research. 2011.Баранцевич Е.Р., Андреев В.В. Возможности лечения хронической боли при пояснично-крестцовой радикулопатии. Врач. 2012;11:13-9. [Barantsevich Ye.R., Andreev V.V. Treatment options for chronic pain in lumbosacral radiculopathy. Vrach. 2012;11:13-9 (in Russ.)]Есин Р.Г., Есин О.Р., Ахмадеева Г.Д., Салихова Г.В. Боль в спине. Казань: Казанский полиграфкомбинат, 2010. 272 с. (Yesin R.G., Yesin O.R., Ahmadeeva G.D., Salihova G.V. Back pain. Kazan': Kazansky poligrafkombinat, 2010. 272 p. (in Russ.)]Chou R., Qaseem A., Snow V., Casey D., Cross J.T. Jr, Shekelle P., Owens D.K.; Clinical efficacy assessment subcommittee of the American College of Physicians; American College of Physicians; American Pain Society Low Back Pain Guidelines Panel. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann. Intern. Med. 2007;147:478-91.Roberts E., Nunes V., Buckner S., Latchem S., Constanti M., Miller P., Doherty M., Zhang W., Birrell F., Porcheret M., Dziedzic K., Bernstein I., Wise E., Conaghan P.G. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann. Rheum. Dis. 2016;75:552-9.Saragiotto B., Machado G., Ferreira M., Pinheiro M.B., Abdel Shaheed C., Maher C.G. Paracetamol for low back pain. Cochrane Database Sys. Rev. 2016;(6):CD012230.Kötter T., da Costa B., Fässler M., Blozik E., Linde K., Jüni P., Reichenbach S., Scherer M. Metamizole-associated adverse events: a systematic review and meta-analysis. PLoS One. 2015;10(4):e0122918.Konijnenbelt-Peters J., van der Heijden C., Ekhart C., Bos J., Bruhn J., Kramers C. Metamizole (Dipyrone) as an Alternative Agent in Postoperative Analgesia in Patients with Contraindications for Nonsteroidal Anti-Inflammatory Drugs. Pain Pract. 2017;17(3):402-8.Gouveia N., Rodrigues A., Ramiro S., Eusébio M., Machado P.M., Canhao H., Branco J.C. The use of analgesic and other pain-relief drugs to manage chronic low back pain: results from a national survey. Pain Pract. 2017;7(3): 353-65.van Tulder M., Becker A., Bekkering T., Breen A., del Real M.T., Hutchinson A., Koes B., Laerum E., Malmivaara A.; COST B Working Group on Guidelines for the Management of Acute Low Back Pain in Primary Care. Chapter 3. European guidelines for the management of acute nonspecific low back pain in primary care. Eur. Spine J. 2006;15 (Suppl. 2):S169-91.Qaseem A., Wilt T., McLean R., Forciea M.A.; Clinical Guidelines Committee of the American College of Physicians. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 2017;166(7):514-30.Brown D., Passmore G. Neural KCNQ (Kv7) channels. Br. J. Pharmacol. 2009;156(8):1 185-95.Fleckenstein J., Sittl R., Averbeck B., Lang P.M., Irnich D., Carr R.W. Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo - therapeutic potential for peripheral neuropathies: results of a randomised controlled trial. J. Transl. Med. 2013;11:34-9.Klinger F., Bajric M., Salzer I., Dorostkar M.M., Khan D., Pollak D.D., Kubista H., Boehm S., Koenig X. 5 Subunit containing GABAA receptors are preferred targets for the centrally acting analgesic flupirtine. Br. J. Pharmacol. 2015;172(20):4946-58.Mueller-Schwefe G. Flupirtine in acute and chronic pain associated with muscle tenseness. Results of a postmarket surveillance study. Fortschr. Med. Orig. 2003;121(1):11-8.Worz R., Stroehmann I. Ruckemschmerzen: Leitlinien der medicamentosen therapie. Munch. Med. Wschr. 2000;142:27-33.Uberall M.A., Mueller-Schwefe G.H., Terhaag B. Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study. Curr. Med. Res. Opin. 2012;28(10):1617-34.Камчатнов П.Р., Батышева Т.Т., Ганжула П.А. и др. Применение катадолона у больных со спондилогенной дорсопатией. Журн. неврол. психиатр. им. С.С. Корсакова. 2006;106(11):46-9. (Kamchatnov P.R., Batysheva T.T., Ganzhula P.A. et al. Application of katadolon in patients with spondylogenic dorsopathy. S.S. Korsakov J. Nevrol. Psychiatry. 2006;106(11)46-9 (in Russ.)]Douros A., Bronder E., Andersohn F., Klimpel A., Thomae M., Sarganas G., Kreutz R., Garbe E. Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study. Br. J. Clin. Pharmacol. 2015;79(6):988-99.Michel M., Radziszewski P., Falconer C., Marschall-Kehrel D, Blot K. Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years. Br. J. Clin. Pharmacol. 2012;73(5):821-5.Nicoletti P., Werk A., Sawle A., Shen Y., Urban T.J., Coulthard S.A., Bjornsson E.S., Cascorbi I., Floratos A., Stammschulte T., Gundert-Remy U., Nelson M.R., Aithal G.P., Daly A.K.; International Drug-induced Liver Injury Consortium. HLA-DRB1*16: 01 -DQB1 *05: 02 is a novel genetic risk factor for flupirtine-induced liver injury. Pharmacogenet. Genomics. 2016;26(5):218-24.Wörz R. Longterm treatment of chronic pain patients with flupirtine on hepatotoxicity and persistent effectiveness from 7 months to 22 years. MMW Fortschr. Med. 2014;156 (Suppl. 4):127-34.Burkhardt H., Wehling M. Non-opioid pain medication in the elderly. Schmerz. 2015;29(4):371-9.